Nasdaq:KYNB
KYNTRA BIO, INC.
A clinical-stage biotechnology company leveraging proprietary platforms to advance oncology therapeutics while managing significant cash burn through strategic financing.
Key Metrics
Investment Thesis
Bull Case
Investors may buy this stock if they believe in the transformative potential of its oncology pipeline and expect successful clinical outcomes that could lead to blockbuster drug approvals. The company's ability to generate positive cash flow from investing activities provides a unique liquidity buffer that can support R&D without immediate dilution.
Bear Case
The stock carries substantial risk due to a massive retained earnings deficit, negative operating cash flow of $138M, and total liabilities significantly outweighing equity. The drastic revenue decline year-over-year suggests potential commercialization challenges or partnership terminations that threaten the company's ability to sustain its clinical programs.
About KYNTRA BIO, INC.
KYNTRA BIO, INC. is a biotechnology company focused on developing novel therapeutic solutions, primarily leveraging its specialized platform to advance clinical-stage assets in oncology and other high-potential disease areas. The company operates within the competitive biopharmaceutical sector, utilizing significant research and development expenditures to drive innovation while managing a lean operational structure with minimal capital expenditures. With substantial deferred revenue and a large paid-in capital base, the firm reflects its reliance on strategic partnerships and public offerings to fund its extensive R&D pipeline and clinical trial activities.
Analysis
Management Discussion
The company reported a net loss of $47.6M in 2024, representing an improvement from prior years despite a sharp contraction in revenue to $29.6M compared to over $140M in previous periods. Cash flow from operations turned negative while cash flow from investing remained positive due to substantial asset sales or disposals totaling $126M, suggesting the company is liquidating assets to offset operational deficits. The balance sheet shows a significant retained earnings deficit of $1.89B and total liabilities exceeding $398M, indicating heavy reliance on financing activities to sustain operations."
Industry Overview
The biotechnology industry is characterized by high R&D costs and long development cycles where companies often operate at a loss until product approval and market entry. Success in this sector depends on securing robust intellectual property, navigating complex regulatory environments, and managing limited capital resources efficiently to advance candidates through clinical trials.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $140.7M | $147.8M | $29.6M |
| Cost of Revenue | $20.3M | $18.8M | $15.6M |
| Gross Profit | $120.5M | $128.9M | $14.1M |
| Operating Expenses | $421.5M | $410.7M | $164.5M |
| Operating Income | $-301.0M | $-281.8M | $-150.4M |
| R&D | $296.8M | $282.9M | $95.7M |
| G&A | $124.7M | $115.3M | $49.3M |
| Stock-Based Comp | $65.6M | $50.8M | $25.2M |
| Depreciation | $10.0M | $9.5M | $2.7M |
| Other OpEx | $0 | $12.6M | $19.5M |
| Non-Operating Income | $6.2M | $-5.1M | $-3.0M |
| Interest Expense | $1.4M | $15.5M | $8.2M |
| Pre-Tax Income | $-294.9M | $-286.9M | $-153.4M |
| Income Tax | $358.0K | $3.0K | $-269.0K |
| Continuing Ops | $-295.2M | $-286.9M | $-153.1M |
| Discontinued Ops | $1.6M | $2.6M | $105.5M |
| Net Income | $-293.7M | $-284.2M | $-47.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-293.7M | $-284.2M | $-47.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $492.8M | $331.6M | $196.5M |
| Cash & Equivalents | $155.7M | $113.7M | $50.5M |
| Marketable Securities | $266.3M | $121.9M | $0 |
| Accounts Receivable | $16.3M | $12.6M | $481.0K |
| Inventory | $40.4M | $41.6M | $3.2M |
| Prepaid Expenses | $14.1M | $41.9M | $31.5M |
| Other Current Assets | $0 | $0 | $110.8M |
| Long-Term Assets | $117.3M | $92.0M | $18.0M |
| PP&E (Net) | $20.6M | $13.1M | $0 |
| Operating Leases | $79.9M | $68.1M | $0 |
| LT Investments | — | — | $0 |
| Other LT Assets | $11.7M | $5.5M | $18.0M |
| Total Assets | $610.1M | $423.5M | $214.5M |
| Current Liabilities | $273.6M | $217.7M | $133.3M |
| Accounts Payable | $30.8M | $18.0M | $5.1M |
| Current Leases | $10.3M | $14.1M | $0 |
| Deferred Revenue | $12.7M | $12.7M | $27.3M |
| Other Current Liab | $0 | $0 | $38.9M |
| Long-Term Liabilities | $338.0M | $368.1M | $264.9M |
| LT Operating Leases | $79.6M | $66.5M | $0 |
| Other LT Liab | $72.7M | $144.0M | $150.1M |
| Total Liabilities | $611.6M | $585.7M | $398.2M |
| Shareholders' Equity | $-1.5M | $-162.2M | $-183.6M |
| Paid-In Capital | $1.54B | $1.64B | $1.67B |
| Retained Earnings | $-1.56B | $-1.84B | $-1.89B |
| AOCI | $-5.7M | $-6.9M | $-5.7M |
| Total L&E | $610.1M | $423.5M | $214.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-293.7M | $-284.2M | $-47.6M |
| Non-Cash Adjustments | $-5.4M | $92.5M | $18.7M |
| Working Capital Changes | $153.1M | $-123.3M | $-109.1M |
| Cash from Operations | $-145.9M | $-315.0M | $-138.0M |
| Capital Expenditures | $3.7M | $2.5M | $266.0K |
| Cash from Investing | $89.1M | $153.7M | $126.0M |
| Cash from Financing | $46.8M | $122.7M | $-255.0K |
| FX Effect | $-5.5M | $-3.4M | $751.0K |
| Net Change in Cash | $-15.5M | $-42.0M | $-11.5M |
| Beginning Cash | $171.2M | $155.7M | $113.7M |
| Ending Cash | $155.7M | $113.7M | $102.2M |
Frequently Asked Questions
How does KYNTRA BIO, INC. make money?
Oncology Therapeutics Development, Strategic Licensing Partnerships, and Clinical Trial Operations
What are the main risks for KYNB?
High cash burn rate of $138M in operations requiring continued equity financing which could dilute shareholders, significant liability leverage with total liabilities nearly double current assets, and the inherent risk of clinical trial failure for its pipeline assets.
What is KYNB's competitive advantage?
Proprietary drug discovery platforms that differentiate its pipeline from competitors, a lean operational cost structure minimizing overhead relative to revenue, and access to substantial non-dilutive funding through strategic collaborations.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.